Samsara BioCapital
Latest statistics and disclosures from Samsara BioCapital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SRRK, MLYS, KLRS, SEPN, ALMS, and represent 79.46% of Samsara BioCapital's stock portfolio.
- Added to shares of these 9 stocks: SRRK (+$57M), IVA (+$24M), KLRS (+$13M), RANI (+$12M), ALMS (+$9.3M), XFOR (+$7.8M), JBIO (+$6.8M), GOSS, STRO.
- Started 4 new stock positions in RANI, IVA, STRO, XFOR.
- Reduced shares in these 10 stocks: LENZ (-$16M), MLYS (-$14M), PVLA (-$11M), AVDL (-$10M), UPB (-$6.1M), CTNM (-$5.7M), AURA, ZYME, SRZN, RYTM.
- Sold out of its positions in AURA, BOLT, LENZ, RYTM, SRZNW, SRZN, Sutro Biopharma, TERN, ZYME, AVDL.
- Samsara BioCapital was a net buyer of stock by $50M.
- Samsara BioCapital has $969M in assets under management (AUM), dropping by 26.55%.
- Central Index Key (CIK): 0001744967
Tip: Access up to 7 years of quarterly data
Positions held by Samsara BioCapital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Samsara BioCapital
Samsara BioCapital holds 21 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Scholar Rock Hldg Corp (SRRK) | 31.3 | $304M | +22% | 6.9M | 44.05 |
|
| Mineralys Therapeutics (MLYS) | 22.0 | $213M | -6% | 5.9M | 36.29 |
|
| Kalaris Therapeutics (KLRS) | 11.3 | $109M | +13% | 13M | 8.44 |
|
| Septerna (SEPN) | 9.1 | $88M | 3.1M | 27.88 |
|
|
| Alumis (ALMS) | 5.8 | $56M | +19% | 5.8M | 9.76 |
|
| Neurogene (NGNE) | 3.6 | $35M | 1.7M | 20.60 |
|
|
| Inventiva Sa Ads (IVA) | 2.5 | $24M | NEW | 5.2M | 4.65 |
|
| Gossamer Bio (GOSS) | 2.3 | $22M | +17% | 7.2M | 3.10 |
|
| Upstream Bio (UPB) | 2.1 | $20M | -23% | 736k | 27.15 |
|
| Aquestive Therapeutics (AQST) | 1.7 | $16M | 2.5M | 6.46 |
|
|
| Jade Biosciences Com New (JBIO) | 1.5 | $15M | +82% | 969k | 15.43 |
|
| Vtv Therapeutics Cl A New (VTVT) | 1.2 | $12M | -20% | 299k | 39.99 |
|
| Rani Therapeutics Hldgs Com Cl A (RANI) | 1.2 | $12M | NEW | 8.5M | 1.35 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 1.1 | $11M | -50% | 105k | 104.67 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.0 | $10M | 75k | 134.85 |
|
|
| X4 Pharmaceuticals Com New (XFOR) | 0.8 | $7.8M | NEW | 2.0M | 4.00 |
|
| Nkarta (NKTX) | 0.7 | $6.5M | -6% | 3.5M | 1.85 |
|
| Arcellx Common Stock (ACLX) | 0.4 | $4.0M | -25% | 61k | 65.20 |
|
| Sutro Biopharma Com Shs (STRO) | 0.2 | $2.4M | NEW | 205k | 11.57 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.1 | $826k | -87% | 72k | 11.43 |
|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 0.0 | $41k | -6% | 124k | 0.33 |
|
Past Filings by Samsara BioCapital
SEC 13F filings are viewable for Samsara BioCapital going back to 2018
- Samsara BioCapital 2025 Q4 filed Feb. 17, 2026
- Samsara BioCapital 2025 Q3 filed Nov. 14, 2025
- Samsara BioCapital 2025 Q2 filed Aug. 14, 2025
- Samsara BioCapital 2025 Q1 filed May 15, 2025
- Samsara BioCapital 2024 Q4 filed Feb. 14, 2025
- Samsara BioCapital 2024 Q3 filed Nov. 14, 2024
- Samsara BioCapital 2024 Q2 filed Aug. 14, 2024
- Samsara BioCapital 2024 Q1 filed May 15, 2024
- Samsara BioCapital 2023 Q4 filed Feb. 14, 2024
- Samsara BioCapital 2023 Q3 filed Nov. 14, 2023
- Samsara BioCapital 2023 Q1 restated filed Aug. 14, 2023
- Samsara BioCapital 2023 Q2 filed Aug. 14, 2023
- Samsara BioCapital 2023 Q1 filed May 15, 2023
- Samsara BioCapital 2022 Q4 amended filed Feb. 15, 2023
- Samsara BioCapital 2022 Q4 filed Feb. 14, 2023
- Samsara BioCapital 2022 Q3 filed Nov. 14, 2022